In the race to develop next-generation ADCs—targeting
TROP2, HER2, EGFR, and beyond—the biggest barriers
aren’t always biological. Hidden pitfalls like inconsistent
target expression, unclear mechanisms of action, and
off-tumor toxicity can derail timelines, inflate costs, and
force costly pivots.